OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Continues to Present Compelling Technical Story


OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP), a biopharmaceutical company making strides in the $7.1 billion prostate cancer treatment space, has been one that sparked our interest lately. We started casing the story back in mid-December, when it was trading around $0.15/share. The message was simple then, and its simple now: The market is still delayed in pricing in any of the company’s probabilistic value as a biotech with advanced progress on the R&D side.

However, that is changing, at least a little. Recent action has seen some solid technical improvement, so we wanted to focus on that aspect of the picture today, given the stock’s recent rip higher out of a symmetric triangle consolidation formed in January and February, to tag relative pattern resistance in the $0.40 area. let’s reintroduce this company.

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.

Companies like OBMP have invested huge sums of money to develop treatments for life-threatening diseases. The surest way to make sure that no new revolutionary treatments are ever created again is adopt new laws that prevent investors from seeing a return on their investments in such projects. While it is likely that a Clinton administration would have acted with nuance enough to preserve investor incentives, markets had embraced the concern that things were at risk. The Trump administration has signaled that it will embrace a market-oriented view, and will likely seek to preserve profitability in the space, particularly for smaller players like OBMP.


There are several stocks situated in the prostate cancer segment. The short list includes the likes of Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX).

 Positive catalysts for the company and the industry.

The company was recently advised by Glenn J. Bubley, M.D. (Associate Professor, Medicine, Harvard Medical School and Director, Genitourinary Medical Oncology, Beth Israel Deaconess Medical Center) that their upcoming study on their pipeline’s lead prostate cancer therapy is a prime candidate for submission to the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute.

CTEP coordinates the clinical therapeutics development program of the Division of Cancer Treatment and Diagnosis (DCTD) by reviewing clinical trials and evaluating their merits for collaboration and funding. OncBioMune is in the process of preparing documentation for submission and consideration by CTEP.

There are several companies that may consider OBMP’s pipeline as worthy of valuing. Hill-Rom Holdings, Inc. (NYSE:HRC) recently paid $330M for Mortara. We also just saw Celgene Corporation (NASDAQ:CELG) take Anokion off the playing field. In similar fashion, and right up our current alley, Pfizer just scooped up Medivation Inc (NASDAQ:MDVN) primarily for their IP related to the prostate cancer market.

But the space has been more active than that, with additional deals such as Kitov Pharmaceuticals Holdings Ltd (ADR) (NASDAQ:KTOV) moving on TyrNovo, among others.


DISCLOSURE: The author is receiving compensation for this article. The views and opinions expressed in this article are those of the authors.. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. TheSultansofSwingTrading receives fees for producing and presenting the Content on this Site along with other media services.  

TAG